Where are cannabinoids heading? Decriminalization and innovation possibilities in Mexico

Abstract

The objective of this research is to analyze the history that Mexico has had in relation to cannabinoids and their current link as drugs or as an element within their research, experimentation and production circuits. Through a qualitative analysis of the bills and related articles, we seek to understand if it is possible or not that these laws promote issues of innovation in the Mexican pharmaceutical market, and that as one of the main consequences the opportunities for innovation can be diminished. In the decriminalization process little has been done to eliminate the stigmas associated with the Cannabis sativa L. plant, broadening the limitations on the use of derivatives this plant, which can generate general health benefits, especially in issues of pain or diseases specific to the Mexican population. The originality of this project lies in the study of cannabinoid drugs from their potential after decriminalization and their ways of being incorporated into pharmaceutical circuits, and concluding that current legislation only allows scientific research and a limited clinical use of cannabinoid drugs, allowing glimpses of areas opportunity for the commercialization of medicines and stimulation of scientific research.